StemCell Therapy

FOSTER CITY, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Vaxcyte, Inc., formerly known as SutroVax, a next-generation vaccine company seeking to improve global health by developing superior and novel vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide, today announced financial results for the third quarter ended September 30, 2020 and provided a business update.

Read the original post:
Vaxcyte Reports Third Quarter 2020 Financial Results and Provides Business Update

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today presented preclinical data on HPN601 for the treatment of solid tumors at the 35th Society for Immunotherapy of Cancer (SITC) virtual annual meeting. HPN601 is the first conditionally active T cell engager program from Harpoon. It targets the tumor antigen epithelial cell adhesion molecule (EpCAM) and is based on Harpoon’s proprietary ProTriTAC™ T cell engager prodrug platform designed to remain inert systemically until its activation in the tumor by tumor-associated proteases and to enable the safe targeting of broadly expressed tumor antigens.

Excerpt from:
Harpoon Therapeutics Presents Encouraging Preclinical Data for HPN601 EpCAM ProTriTAC™ Program at 35th SITC Annual Meeting

LYON, France and CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Nasdaq & Euronext: ERYP), announced today that its CEO, Gil Beyen, will present an update at the Jefferies Virtual London Healthcare Conference at 12:00pm EST / 05:00pm GMT / 6:00pm CET on November 18, 2020.

Read the rest here:
ERYTECH to Present at Jefferies Virtual Healthcare Conference

BRIDGEWATER, N.J., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and Andrew Einhorn, Chief Financial Officer, will present at the 2020 Jefferies Virtual London Healthcare Conference as follows:

See the original post here:
Osmotica Pharmaceuticals plc to Present at 2020 Jefferies Virtual London Healthcare Conference

CAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the field of cellular metabolism to treat cancer and rare genetic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company’s first-in-class pyruvate kinase R (PKR) activator mitapivat for the treatment of patients with sickle cell disease. Mitapivat is an investigational, oral, small molecule allosteric activator of wild-type and a variety of mutated PKR enzymes.

Read more from the original source:
Agios Announces FDA Orphan Drug Designation Granted to Mitapivat for Treatment of Sickle Cell Disease

Increasing Placebo Responses in PTSD Drug Trials Raise Questions About Current Methods of Measuring or Analyzing PTSD Symptom Change Over Time

See the rest here:
Tonix Pharmaceuticals Outlines New Statistical Method to Analyze Future PTSD Studies at the 3rd Annual Neuropsychiatric Drug Development Summit

LEXINGTON, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced that the Company plans to participate in the upcoming Canaccord Genuity Virtual MedTech & Diagnostics Forum.

Read the original post:
T2 Biosystems to Participate in the Canaccord Genuity Virtual MedTech & Diagnostics Forum

VANCOUVER, British Columbia, Nov. 12, 2020 (GLOBE NEWSWIRE) -- EXMceuticals Inc. (CSE: EXM) (FSE: A2PAW2) (the “Company” or “EXM”) is providing this bi-weekly default status report in accordance with National Policy 12-203 Management Cease Trade Orders (“NP 12-203”). On October 23, 2020, the Company announced that, for reasons set out in its news release of October 23, 2020, the filing of its annual audited financial statements for the year ended June 30, 2020, the accompanying management’s discussion and analysis and the related CEO and CFO certifications (collectively, the “Annual Filings”) would not be filed by the prescribed deadline of October 28, 2020.

See the rest here:
EXMceuticals Provides Bi-Weekly Default Status Report

WOODCLIFF LAKE, NJ, Nov. 12, 2020 (GLOBE NEWSWIRE) -- via NewMediaWire -- Timber Pharmaceuticals, Inc. ("Timber" or the “Company”) (NYSE American: TMBR), a biopharmaceutical company focused on the development and commercialization of treatments for rare and orphan dermatologic diseases, today provided a business update and announced financial results for the third quarter of 2020, ended September 30, 2020.

See the original post:
Timber Pharmaceuticals Provides Business Update and Announces Third Quarter 2020 Financial Results

Highlights include closing $19.2 million public offering, uplisting to Nasdaq, and positive progress with multiple candidates currently in Processa’s clinical drug pipeline Highlights include closing $19.2 million public offering, uplisting to Nasdaq, and positive progress with multiple candidates currently in Processa’s clinical drug pipeline

Read more from the original source:
Processa Pharmaceuticals Announces Third Quarter 2020 Results, Provides Corporate Update

SPARTA, N.J., Nov. 12, 2020 (GLOBE NEWSWIRE) -- PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), a late-stage specialty pharmaceutical company focused on developing its clinically-validated and patent-protected PLxGuard™ delivery system to provide more effective and safer products, VAZALORE™ 325 mg and VAZALORE™ 81 mg (referred to together as “VAZALORE”™), announced today that the Company has rescheduled its 2020 third quarter financial results call to Monday, November 16, 2020.

View post:
PLx Pharma Inc. 2020 Third Quarter Financial Results and Business Update Conference Call Rescheduled to November 16, 2020

WATERTOWN, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Aileron Therapeutics (NASDAQ:ALRN) today reported business highlights and financial results for the third quarter ended September 30, 2020.

View post:
Aileron Therapeutics Reports Third Quarter 2020 Financial Results and Business Highlights

LA JOLLA, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Principal Investigators Leila Gobejishvili, PhD and Craig McClain, MD at the University of Louisville School of Medicine presented positive results of the in-vitro and in-vivo studies that evaluated MN-001 (tipelukast, referred to as D46 in the presentation) for its anti-liver fibrotic effect in human hepatic stellate cells (HSCs) and in an acute liver injury model at the Liver Meeting Digital Experience™ 2020 (TLMdX™), the annual meeting of the American Association for the Study of Liver Diseases (AASLD).

Read more from the original source:
MediciNova Announces Presentation of Positive Findings on MN-001 (tipelukast) in Acute Liver Injury Model at The Liver Meeting Digital Experience™...

According to Bellator middleweight contender Austin Vanderford, former UFC star Paige VanZant intends to return to mixed martial arts in the future.

Vanderford, who is married to VanZant, recently returned to the Bellator cage where he picked up an impressive victory over Vinicius de Jesus. Post-fight, he shed some light on what the future holds for his wife.

VanZant recently parted ways with the UFC, and inked an exclusive, multi-fight deal with BKFC. She is far and away the highest-profile fighter the upstart bare knuckle organization has signed to date.

According to Vanderford, VanZant will be using this time with BKFC to improve her striking for the benefit of her eventual return to MMA.

She felt at this point in her career she needed to make some changes to continue to compete with the top girls, Vanderford told The Telegraph. What shes going to do now will extend the longevity of her career. I know that sounds ironic since shes going to fight in bare knuckle. But shes only 26 and this gives her the opportunity to work on some things. Really work on her striking.

Shes more than likely going to come back to MMA, Vanderford added, shedding some light on what the future holds for VanZant. She wants to try and work on becoming a more well-rounded fighter. Im biased, but in my opinion she will be one of the best in the world.

Paige VanZant closed out her run with the UFC in the summer, when she was submitted by Amanda Ribas in the final bout on her current UFC contract. She then signed with BKFC, but has yet to make her debut with the organization. The former UFCs stars bare knuckle debut was originally expected to go down in November, but is now being targeted for Super Bowl weekend in February.

What do you think the future holds for VanZant?

Read more:
BKFC run will preserve the longevity of Paige VanZants MMA career - BJPENN.COM

It can be easy to believe that yoga is a practice for the young especially as the vast majority of images depicting yoga feature very youthful women engaging in impressive feats of flexibility. However, we do not need gymnastic skills, years of training and fewer than forty candles on the birthday cake to make yoga part of our lives. As a form of exercise and meditative practice, we can embrace yoga at any stage of life, and gain many benefits from doing so.

In recent years, some fantastic yoga practitioners have been working hard to gain representation and depict the true diversity of yoga. Yoga is a broad and adaptable practice that can be used by anyone (whatever their health status, body type, gender, or ethnicity), and it can be particularly helpful as we grow older.

One key factor that separates yoga from other forms of exercise is that in bringing attention to and coordinating the breath with the movement of the body, yoga is a practice in mindfulness. It holistically supports our wellbeing by promoting a mind-body connection and can help us both prevent and ease the symptoms of many common health conditions.

1. Lowering the risk of heart disease

More:
Seven Ways That Yoga Helps Us As We Age - Longevity LIVE - Longevity LIVE

Every day, the kidneys filter around 120 150 quarts(4800 6000 ounces) of fluid, said Medical News Today.

The health site added: Of these, approximately one to two quarts (40 80 ounces) are removed from the body in the form of urine, and the rest is recovered by the bloodstream.

Water is essential for the kidneys to function and if the kidneys do not function properly, waste products andexcess fluid can build up inside the body.

Untreated,chronic kidney diseasecan lead to kidney failure with the organs not working, and either dialysis or kidney transplantation is required.

Urinary tract infections are the second most common type of infection in the body.

If infections spread to the upper urinary tract, including the kidneys, permanent damage can result. Sudden, or acute, kidney infections can be life-threatening, particularly if septicaemia occurs.

Drinking plenty of water is a simple way to reduce the risk of developing a serious infection.

Excerpt from:
How to live longer: Water helps fight off infections, reduce cancer risk and boost longevi - Express

The global longevity and anti-senescence therapies market should grow from $329.8 million in 2018 to $644.4 million by 2023 with a compound annual growth rate (CAGR) of 14.3% during 2018-2023.

Report Scope:

The scope of this report is broad and covers various therapies currently under trials in the global longevity and anti-senescence therapy market. The market estimation has been performed with consideration for revenue generation in the forecast years 2018-2023 after the expected availability of products in the market by 2023. The global longevity and anti-senescence therapy market has been segmented by the following therapies: Senolytic drug therapy, Gene therapy, Immunotherapy and Other therapies which includes stem cell-based therapies, etc.

Revenue forecasts from 2028 to 2023 are given for each therapy and application, with estimated values derived from the expected revenue generation in the first year of launch.

The report also includes a discussion of the major players performing research or the potential players across each regional longevity and anti-senescence therapy market. Further, it explains the major drivers and regional dynamics of the global longevity and anti-senescence therapy market and current trends within the industry.

Click Here to Get Sample Premium Report @ https://www.trendsmarketresearch.com/report/sample/11698

The report concludes with a special focus on the vendor landscape and includes detailed profiles of the major vendors and potential entrants in the global longevity and anti-senescence therapy market.

Report Includes:

71 data tables and 40 additional tables An overview of the global longevity and anti-senescence therapy market Analyses of global market trends, with data from 2017 and 2018, and projections of compound annual growth rates (CAGRs) through 2023 Country specific data and analysis for the United States, Canada, Japan, China, India, U.K., France, Germany, Spain, Australia, Middle East and Africa Detailed description of various anti-senescence therapies, such as senolytic drug therapy, gene therapy, immunotherapy and other stem cell therapies, and their influence in slowing down aging or reverse aging process Coverage of various therapeutic drugs, devices and technologies and information on compounds used for the development of anti-ageing therapeutics A look at the clinical trials and expected launch of anti-senescence products Detailed profiles of the market leading companies and potential entrants in the global longevity and anti-senescence therapy market, including AgeX Therapeutics, CohBar Inc., PowerVision Inc., T.A. Sciences and Unity Biotechnology

Summary

Global longevity and anti-senescence therapy market deals in the adoption of different therapies and treatment options used to extend human longevity and lifespan. Human longevity is typically used to describe the length of an individuals lifetime and is sometimes used as a synonym for life expectancy in the demography. Anti-senescence is the process by which cells stop dividing irreversibly and enter a stage of permanent growth arrest, eliminating cell death. Anti-senescence therapy is used in the treatment of senescence induced through unrepaired DNA damage or other cellular stresses.

Global longevity and anti-senescence market will witness rapid growth over the forecast period (2018-2023) owing to an increasing emphasis on Stem Cell Research and an increasing demand for cell-based assays in research and development.

An increasing geriatric population across the globe and a rising awareness of antiaging products among generation Y and later generations are the major factors expected to promote the growth of global longevity and anti-senescence market. Factors such as a surging level of disposable income and increasing advancements in anti-senescence technologies are also providing traction to the global longevity and anti-senescence market growth over the forecast period (2018-2023).

According to the National Institutes of Health (NIH), the total geriatric population across the globe in 2016 was over REDACTED. By 2022, the global geriatric population (65 years and above) is anticipated to reach over REDACTED. An increasing geriatric population across the globe will generate huge growth prospectus to the market.

Senolytics, placenta stem cells and blood transfusions are some of the hot technologies picking up pace in the longevity and anti-anti-senescence market. Companies and start-ups across the globe such as Unity Biotechnology, Human Longevity Inc., Calico Life Sciences, Acorda Therapeutics, etc. are working extensively in this field for the extension of human longevity by focusing on study of genomics, microbiome, bioinformatics and stem cell therapies, etc. These factors are poised to drive market growth over the forecast period.

Global longevity and anti-senescence market is projected to rise at a CAGR of REDACTED during the forecast period of 2018 through 2023. In 2023, total revenues are expected to reach REDACTED, registering REDACTED in growth from REDACTED in 2018.

The report provides analysis based on each market segment including therapies and application. The therapies segment is further sub-segmented into Senolytic drug therapy, Gene therapy, Immunotherapy and Others. Senolytic drug therapy held the largest market revenue share of REDACTED in 2017. By 2023, total revenue from senolytic drug therapy is expected to reach REDACTED. Gene therapy segment is estimated to rise at the highest CAGR of REDACTED till 2023. The fastest growth of the gene therapy segment is due to the Large investments in genomics. For Instance; The National Human Genome Research Institute (U.S.) had a budget grant of REDACTED for REDACTED research projects in 2015, thus increasing funding to REDACTED for approximately REDACTED projects in 2016.

More Info of Impact Covid19 @ https://www.trendsmarketresearch.com/report/covid-19-analysis/11698

Read the original:
Longevity and Anti-senescence Therapy Market Top Participant To Focus On Regional Expansion the COVID-19 - The Daily Philadelphian

Lake District

The Lake District is a popular destination for anyone wanting to be at one with nature. The Lake District National Park attracts tourists from across the globe thanks to the spectacular scenery, wildlife, history, and culture on offer. Each year, over 15 million visitors head to the location for a fantastic break away. But surely so many visitors will mean this shouldnt be revered as a go-to off-grid getaway? Wrong! There are still many secluded locations off the beaten track which can satisfy your needs.

Head to Ennerdale Valley and youll be met by nothing but wild beauty. While its not the easiest spot to get to, youll be escaping the crowds and shops and instead be met with an abundance of great walks and cycle tracks. Ennerdale Water is also the most westerly lake in the Lake District, so why not look at the nearby town of Whitehaven for your rural base?

While the Georgian town is continuing to grow in size, it is still one of the 51 Gem Towns in the UK. This title is given to those areas which were considered to be particularly splendid and precious by the Council for British Archaeology in 1964s response to the Traffic in Towns Buchanan Report.

Covid-19 was the cause for the search for Lake District holidays to plummet, but it is beginning to rise once again. For the perfect rural retreat near the Lake District, one of Airbnbs top choices includes a quaint camping pod. Completely off-grid, this accommodation is described as the perfect alternative.

Search rural getaways on Google, and the Peak District is one of the most popular destinations. Known for its picturesque postcard appearance, the Peak District is home to magnificent lakes, reservoirs, and nature reserves. Founded in 1951, it was the first of Britains 15 national parks. Each year, over 13 million visitors descend on the Peak District, with local attractions including Hathersage the reputed grave site of Robin Hood and Tideswell, the 14th century cathedral of the Peak.

Like the Lake District, it is the ideal choice for being at one with nature thanks to its walkways and scenic views. But, while the likes of Buxton is popular with tourists thanks to its range of restaurants and bars, and Matlock has the River Derwent on its doorstep, and there are hidden gems that can help you get a real feel of seclusion on your next off-grid getaway.

While Eyam may be best known for a breakout of the Black Death in 1665, nowadays its a beautifully peaceful village which is home to approximately 1,000 people. Its the typical village that stood still in time and can give you the feel of what life may have been like in yesteryear. With buildings as old as the 9th century, there are many magical stories to pick up on your travels including a visit to the grave of Little John in the local churchyard!

A search on Airbnb unearths many hidden gems of its own, with cottages, a 17th century mill, a woodcutters cabin, and a Mediterranean-style basement flat all gaining rave reviews in the area. All would provide the perfect destination for an off-grid getaway.

With rural areas covering 85 per cent of the UK, but less than one in five of us living there, we are inundated with amazing backdrops for your next off-grid adventure. Do your research fully and bag yourself the perfect location in which to unwind in on your next trip.

*correct as of 1st June 2020

https://www.bbc.co.uk/news/business-52066454

https://www.visitpeakdistrict.com/explore/towns-and-villages

https://www.campsites.co.uk/inspiration/national-parks/secret-places-in-the-lake-district

More here:
Revealed: The UK's Best Off-Grid Getaways - Longevity LIVE - Longevity LIVE

Texas football is currently locked in a battle with the West Virginia Mountaineers in a critical game at home on Nov. 7. West Virginia and Texas both came into this game with identical records, sitting at 4-2 (3-2 Big 12) a piece. Texas was coming off a nice win last weekend in upset fashion on the road over the previously undefeated and No. 6 ranked Oklahoma State Cowboys in overtime, by the final score of 41-34.

Meanwhile, West Virginia is coming off a nice win of their own from last weekend. West Virginia also took care of business against a ranked Big 12 opponent on Oct. 31, by dominating the previously No. 16 ranked Kansas State Wildcats by the final score of 37-10. Both Texas and West Virginia had momentum trending in the right direction heading into this weekend.

All eyes were on the Longhorns coming into this game to see if head coach Tom Herman can keep his team trending in the right direction and build a three-game winning streak. Texas was just shy of a touchdown favorite ahead of kick off, so they should be able to take care of business against the Mountaineers.

Questions are still being asked about the Longhorns chances to make the Big 12 Championship Game this season. The win over Oklahoma State did restore a lot of hope that Herman can guide the Longhorns to at least earn a spot in the Big 12 Championship Game. They now sit firmly in contention with the likes of the Iowa State Cyclones and Oklahoma schools to get a spot in the Big 12 Title Game.

But ESPNs Kirk Herbstreit found some doubt in the Longhorns chances to make it back to the Big 12 Championship Game for the first time since 2018. Herbstreit projected his conference title game matchup on Nov. 7, saying that it will come down to Iowa State and Oklahoma.

While he did say that he believes Texas will take care of business against West Virginia this weekend, he doesnt believe in this team over the long-term. That does make a lot of sense since the Longhorns were anything but consistent under Hermans direction the last few years.

After the Longhorns take on the Mountaineers, theyre set to face the lowly Kansas Jayhawks on Nov. 21. They have a bye week once the West Virginia game wraps up. The back end of the schedule doesnt look to be as difficult as the front half.

Visit link:
Herbstreit doesnt buy into longevity of Texas football in 2020 - Hook'em Headlines

When Disney acquired Fox for $70 billion, it took full ownership of Fox-owned IP that can now be reimagined, rebooted, and remade under the Mouse House. Enter the upcoming Disney+ streaming series Home Alone, a reboot of director Chris Columbus and producer/writer John Hughes 1990 comedy classic starring Macaulay Culkin, Joe Pesci, Daniel Stern, and Catherine OHara. The film earned over $470 worldwide for Fox and is now getting a Disney spin from Dirty Grandpa director Dan Mazer and a cast that includes Archie Yates, Rob Delaney, and Ellie Kemper.

In a new interview with Insider, Columbus rails against the idea of rebooting his beloved comedy favorite. The director revealed nobody from the Disney+ production got in touch with him about jumpstarting a new Home Alone television franchise not that Columbus thinks a Home Alone reboot is needed.

Its a waste of time as far as Im concerned. Whats the point? Columbus said. Im a firm believer that you dont remake films that have had the longevity of Home Alone. Youre not going to create lightning in a bottle again. Its just not going to happen. So why do it? Its like doing a paint-by-numbers version of a Disney animated film a live-action version of that. Whats the point? Its been done. Do your own thing. Even if you fail miserably, at least you have come up with something original.

RelatedRelated

Before the Disney-Fox merger, the latter studio was developing its own reimagining of Home Alone called Stoned Alone. The plan was for Ryan Reynolds to star in the leading role of an adult stoner who finds himself fending off robbers while alone over the holidays and high on marijuana.

God only knows what that will be, Columbus said. A stoner version of Home Alone? Listen, have fun. I just feel, do something new. Life is short.

The Home Alone reboot cast for Disney+ also includes Kenan Thompson, Ally Maki, and Chris Parnell. Yates, one of the young breakout performers from Taika Waititis Oscar winner Jojo Rabbit, is starring in the child role made famous by Culkin. Disney+s Home Alone reboot had been filming when the industry shut down in March amid the pandemic. No release date has been set.

Sign Up: Stay on top of the latest breaking film and TV news! Sign up for our Email Newsletters here.

Read more from the original source:
Home Alone Director Chris Columbus: Disney+ Is Wasting Its Time Rebooting the Film - IndieWire